A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica. 2019 Jul 05;: Authors: Beksac M, Cengiz Seval G, Kanellias N, Coriu D, Rosiñol L, Ozet G, Goranova-Marinova V, Unal A, Bila J, Ozsan H, Ivanaj A, Balić LI, Kastritis E, Bladé J, Dimopoulos MA Abstract Here, we are reporting the outcome of 226 myeloma patients presenting with extramedullary plasmacytoma or paraosseous involvement in a retrospective study conducted in 19 centers from 11 countries. Extramedullary disease was detected at diagnosis or relapse between January 2010 and November 2017. Extramedullary plasmacytoma and paraosseous involvement were observed in 130 patients at diagnosis (92/38) and in 96 at relapse (84/12). The median time from multiple myeloma diagnosis to the development of extramedullary disease was 25.1 months (range 3.1-106.3 months) in the relapse group (median follow-up: 15 months). Imaging approach for extramedullary disease was computed tomography (n: 133), positron emission tomography combined with computed tomography (n: 50) or magnetic resonance imaging (n: 35). The entire group received median two lines of treatment and autologous stem cell transplantation (44%) following the diagnosis of extramedullary disease. Complete response was higher for paraosseous involvement vs. extramedullary plasmacytoma at diagnosis...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research